Plaque imaging with MR catheter enters U.S. trials
Three U.S. sites in January began recruiting patients to test the safety and efficacy of an intravascular MRI catheter that preclinically differentiates the lipid-rich core of vulnerable plaque from other components.
Three U.S. sites in January began recruiting patients to test the safety and efficacy of an intravascular MRI catheter that preclinically differentiates the lipid-rich core of vulnerable plaque from other components. If proven effective, the technique could dramatically change treatment options for patients with coronary artery disease, according to principal investigator Dr. Ron Waksman, associate chief of cardiology at Washington Hospital Center in Washington, DC.
The objective of TOP-IMAGE II, which intends to enroll 100 subjects, is to assess the safety and functional performance of the device in patients whose plaques are not associated with high-grade stenosis.
Waksman, who spoke at the 2007 International Symposium on Endovascular Therapy, said intravascular ultrasound cannot visualize vulnerable plaques' fibrous cap and is only 37% sensitive for detecting plaque rupture. TopSpin Medical of Israel makes the IntraVascular MRI catheter.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
